Amferia, a Swedish medtech company, has made significant strides in the fight against antimicrobial resistance. Recently, the company raised €1.2 million to advance its unique hydrogel technology aimed at combating bacterial infections.
This investment is pivotal for accelerating the clinical development of Amferia’s innovative platform, potentially transforming both human and animal healthcare sectors by addressing complex bacterial challenges.
Amferia, the Swedish medtech innovator, has successfully raised €1.2M, driven by both existing stakeholders and new supporters like Chalmers Ventures. This investment will significantly bolster Amferia’s pioneering work in antimicrobial peptide technology, essential in tackling antibiotic-resistant bacteria. The goal aligns with the broader mission of fortifying global infection control, addressing a pressing public health threat.
Alongside the new funding, Amferia has forged a commercial agreement with Orkla Wound Care to introduce an innovative wound dressing for animals. This product not only aids healing but also addresses resistant bacterial infections, marking a pivotal expansion of Amferia’s technology into animal health.
The World Health Organisation warns of antibiotic-resistant infections becoming a predominant cause of death within a decade. Amferia’s hydrogel technology is being evaluated for further applications such as deep wound sprays and medical implant coatings. “Bacterial infections could overshadow cancer and heart disease,” stated Anand Rajasekharan, CEO of Amferia. Their technology imitates natural immune processes, offering a stable environment for antimicrobial peptides to function effectively.
While initially focused on veterinary solutions, Amferia is actively broadening its technology’s scope to human health applications. The company’s proprietary technology includes wound care products aimed at combatting infections resistant to standard treatments, contributing significantly to future healthcare solutions.
With the newly acquired funds, Amferia aims to achieve CE marking and FDA clearance, crucial for human application expansion. “This investment is pivotal for Amferia’s progress,” commented Jonas Bergman at Chalmers Ventures. It will foster strategic alliances, facilitating broader market integration.
Amferia’s strides in the medtech sector highlight the urgent need for advanced infection control solutions. Their hydrogel platform demonstrates potential across various health sectors, underscoring a vital shift in both human and animal healthcare dynamics.
Amferia’s recent €1.2M funding round represents a crucial step in addressing the growing threat of antimicrobial resistance.
With continued innovation and strategic partnerships, Amferia is poised to make significant contributions to global healthcare solutions.
